Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Acumen Pharmaceuticals In...

    NASDAQ: ABOS · Real-Time Price · USD
    1.14
    0.07 (6.54%)
    At close: Jun 16, 2025, 3:59 PM
    1.14
    0.44%
    After-hours: Jun 16, 2025, 04:04 PM EDT

    Acumen Pharmaceuticals Statistics

    Share Statistics

    Acumen Pharmaceuticals has 60.57M shares outstanding. The number of shares has increased by 0% in one year.

    Shares Outstanding

    n/a
    		 60.57M

    Shares Change (YoY)

    n/a
    		 0%

    Shares Change (QoQ)

    n/a
    		 0%

    Owned by Institutions (%)

    n/a
    		 70.74%

    Shares Floating

    n/a
    		 44.2M

    Failed to Deliver (FTD) Shares

    n/a
    		 3,418

    FTD / Avg. Volume

    n/a
    		 1.44%

    Short Selling Information

    The latest short interest is 2.55M, so 4.2% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 2.55M

    Short % of Shares Out

    n/a
    		 4.2%

    Short % of Float

    n/a
    		 5.67%

    Short Ratio (days to cover)

    n/a
    		 10.35

    Valuation Ratios

    The PE ratio is -1.01 and the forward PE ratio is -0.64. Acumen Pharmaceuticals's PEG ratio is -0.02.

    PE Ratio

    n/a
    		 -1.01

    Forward PE

    n/a
    		 -0.64

    PS Ratio

    n/a
    		 0

    Forward PS

    n/a
    		 1.2

    PB Ratio

    n/a
    		 0.57

    P/FCF Ratio

    n/a
    		 -1.2

    PEG Ratio

    n/a
    		 -0.02
    Financial Ratio History

    Enterprise Valuation

    Currently the Enterprise Value (EV) is not available for Acumen Pharmaceuticals.

    EV / Sales

    n/a
    		 n/a

    EV / EBITDA

    n/a
    		 n/a

    EV / EBIT

    n/a
    		 n/a

    EV / FCF

    n/a
    		 n/a

    Financial Position

    The company has a current ratio of 6.46, with a Debt / Equity ratio of 0.16.

    Current Ratio

    n/a
    		 6.46

    Quick Ratio

    n/a
    		 6.46

    Debt / Equity

    n/a
    		 0.16

    Debt / EBITDA

    n/a
    		 -0.3

    Debt / FCF

    n/a
    		 -0.34

    Interest Coverage

    n/a
    		 -28.03

    Financial Efficiency

    Return on Equity is n/a and Return on Invested Capital is n/a.

    Return on Equity

    n/a
    		 n/a

    Return on Assets

    n/a
    		 n/a

    Return on Invested Capital

    n/a
    		 n/a

    Revenue Per Employee

    n/a
    		 n/a

    Profits Per Employee

    n/a
    		 $-1,677,524.59

    Employee Count

    n/a
    		 61

    Asset Turnover

    n/a
    		 0

    Inventory Turnover

    n/a
    		 n/a

    Taxes

    Income Tax

    n/a
    		 n/a

    Effective Tax Rate

    n/a
    		 0%

    Stock Price Statistics

    The stock price has increased by -54.4% in the last 52 weeks. The beta is 0.05, so Acumen Pharmaceuticals's price volatility has been higher than the market average.

    Beta

    n/a
    		 0.05

    52-Week Price Change

    n/a
    		 -54.4%

    50-Day Moving Average

    n/a
    		 1.05

    200-Day Moving Average

    n/a
    		 1.76

    Relative Strength Index (RSI)

    n/a
    		 54.55

    Average Volume (20 Days)

    n/a
    		 236,977

    Income Statement

    Revenue

    n/a
    		 n/a

    Gross Profit

    n/a
    		 n/a

    Operating Income

    n/a
    		 -114.02M

    Net Income

    n/a
    		 -102.33M

    EBITDA

    n/a
    		 -98.08M

    EBIT

    n/a
    		 -98.26M

    Earnings Per Share (EPS)

    n/a
    		 -1.71
    Full Income Statement

    Balance Sheet

    The company has 35.63M in cash and 29.7M in debt, giving a net cash position of 5.92M.

    Cash & Cash Equivalents

    n/a
    		 35.63M

    Total Debt

    n/a
    		 29.7M

    Net Cash

    n/a
    		 5.92M

    Retained Earnings

    n/a
    		 -325.13M

    Total Assets

    n/a
    		 204.48M

    Working Capital

    n/a
    		 135.63M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -86.22M and capital expenditures -16K, giving a free cash flow of -86.23M.

    Operating Cash Flow

    n/a
    		 -86.22M

    Capital Expenditures

    n/a
    		 -16K

    Free Cash Flow

    n/a
    		 -86.23M

    FCF Per Share

    n/a
    		 -1.44
    Full Cash Flow Statement

    Margins

    Gross Margin

    n/a
    		 n/a

    Operating Margin

    n/a
    		 n/a

    Pretax Margin

    n/a
    		 n/a

    Profit Margin

    n/a
    		 n/a

    EBITDA Margin

    n/a
    		 n/a

    EBIT Margin

    n/a
    		 n/a

    FCF Margin

    n/a
    		 n/a

    Dividends & Yields

    ABOS does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 n/a

    FCF Yield

    n/a
    		 n/a
    Dividend Details

    Analyst Forecast

    The average price target for ABOS is $7, which is 514% higher than the current price. The consensus rating is "Buy".

    Price Target

    n/a
    		 $7

    Price Target Difference

    n/a
    		 514%

    Analyst Consensus

    n/a
    		 Buy

    Analyst Count

    n/a
    		 3
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Scores

    Altman Z-Score

    n/a
    		 -2.72

    Piotroski F-Score

    n/a
    		 1

    Add to Watchlist